Skip to main content

Table 5 Clinical and socio-demographic factors associated with not getting DST among patients with presumptive MDR-TB, District Bhopal, India (2014)

From: High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India

Variable Total Not tested for RR (0.95 CI) aRR (0.95 CI)a
[n] DST [n (%)]   
Total 770 459 (60)   
Age (years)
 • <14 7 4 (57) 0.9 (0.5, 1.9) 1.0 (0.6, 1.9)
 • 14-44 513 301 (59) 1.0 (0.9, 1.2) 1.0 (0.9, 1.2)
 • 45-64 203 118 (58) Ref Ref
 • >/= 65 47 36 (77) 1.3 (1.1, 1.6)* 1.3 (1.1, 1.7)*
Gender
 • Male 520 314 (60) 1.0 (0.9, 1.2) 1.1 (1.0, 1.2)
 • Female 250 145 (58) Ref Ref
Health facility     
 • Primary/Secondary level 362 208 (58) 1.0 (0.9, 1.1) 1.0 (0.9, 1.1)
 • District level 273 159 (58) Ref Ref
 • Medical college 135 92 (68) 1.2 (1.00, 1.4) 1.2 (1.02, 1.4)*
Presumptive MDR-TB criteria
 • Previously treated – recurrent 251 128 (51) 1.2 (0.9,1.5) 1.3 (1.0, 1.6)*
 • Treatment after failure 22 11 (50) 1.2 (0.7, 1.9) 1.3 (0.8, 2.0)
 • Treatment after loss to follow up 51 33 (65) 1.5 (1.2, 2.0)* 1.5 (1.1, 2.1)*
 • Previously treated – others 311 229 (74) 1.7 (1.4, 2.1)* 1.6 (1.1, 2.3)*
 • Follow up smear + 132 56 (42) Ref Ref
 • New patient with TB-HIV 3 2 (67) 1.6 (0.7,3.6) 1.8 (0.8, 4.2)
Site of Tuberculosis
 • Extra pulmonary 89 72 (81) 1.6 (1.4, 1.9)* 1.5 (1.0, 2.2)*
 • Pulmonary – smear negative 248 172 (69) 1.4 (1.2, 1.6)* 1.2 (0.8, 1.7)
 • Pulmonary – smear positive 433 215 (50) Ref Ref
Quarter
 • January – March 2014 101 63 (62) Ref Ref
 • April – June 2014b 238 144 (61) 0.97 (0.8, 1.2) 0.8 (0.7, 0.98)*
 • July – September 2014 223 132 (59) 0.95 (0.8, 1.1) 0.8 (0.7, 0.99)*
 • October – December 2014 208 120 (58) 0.9 (0.8, 1.1) 0.8 (0.6, 0.95)*
  1. MDR-TB Multi drug-resistant tuberculosis, DST Drug susceptibility testing
  2. aadjusted relative risk calculated using poisson regression with robust variance estimates (enter method)
  3. *p < 0.05
  4. bLPA was used as DST for smear positive patient; Cb-NAAT was introduced as DST for smear negative patient in quarter 2